Obinutuzumab binds CD20 on B cells; its Fc engages Fcγ receptors on effector cells (e.g., CD16a on NK cells, CD16b on neutrophils) to mediate ADCC/ADCP and also induces direct cell death of CD20+ B cells. CD16b-expressing cells are not targeted or killed.